Trillium Asset Management LLC Sells 4,366 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Trillium Asset Management LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 83,329 shares of the medical research company’s stock after selling 4,366 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.1% of Trillium Asset Management LLC’s portfolio, making the stock its 18th largest holding. Trillium Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $43,351,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in TMO. Legacy Investment Solutions LLC bought a new stake in Thermo Fisher Scientific during the third quarter valued at $26,000. Barrett & Company Inc. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. FPC Investment Advisory Inc. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $28,000. Missouri Trust & Investment Co bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Finally, Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.4 %

Thermo Fisher Scientific stock opened at $521.42 on Wednesday. The firm has a 50 day moving average of $547.72 and a 200 day moving average of $557.48. The firm has a market capitalization of $196.71 billion, a price-to-earnings ratio of 31.54, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.33%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.41%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research analyst reports. Scotiabank lifted their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a report on Monday, February 3rd. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research note on Friday, January 10th. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Citigroup reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Finally, Raymond James reissued an “outperform” rating and set a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $653.23.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.